Navigation Links
InterMune Reports First Quarter 2011 Financial Results and Business Highlights
Date:4/28/2011

rs: T.E. King, C. Albera, R.M. du Bois, W. Bradford, U. Costabel, P.W. Noble, S.A. Sahn, D. Valeyre, p.A5302
  • Presentation: Tuesday, May 17, 3:15 p.m., Korbel Ballroom 2A-3A (Lower Level), Colorado Convention Center
  • This presentation will include analyses of lung function change at one year from three Phase 3 studies and these analyses show a clinically meaningful and statistically significant pirfenidone treatment effect at this time point.
  • B102 Poster Discussion: 110. The Effect of Treatment with Pirfenidone on Progression-Free Survival in Patients with Idiopathic Pulmonary Fibrosis (IPF): Exploratory Analysis of Outcomes Using Novel Criteria for Disease Progression
  • Authors: S.A. Sahn, C. Albera, R.M. du Bois, W. Bradford, U. Costabel, T.E. King, P.W. Noble, D. Valeyre, p.A3810
  • Poster Viewing and Discussion: Monday, May 16, - 2:00 p.m. - 4:30 p.m., Korbel Ballroom 1A-1B (Lower Level), Colorado Convention Center

  • Hepatology:

  • In January 2011, InterMune announced that it had reached a new agreement with Roche that will focus on research to identify and develop next-generation protease inhibitors for the treatment of HCV.  Under terms of the agreement, Roche will fund all research costs related to the programs for the term of the agreement, July 1, 2010 to June 30, 2011.

  • First Quarter 2011 Financial Results (Unaudited)InterMune reported total revenue in the first quarter of 2011 of $6.4 million, compared with $6.1 million in the first quarter of 2010, reflecting increased collaboration revenue under the company's new research agreement with Roche, partially offset by lower off-label physician prescriptions of Actimmune® (interferon gamma-1b) for the treatment of IPF, which InterMune does not promote.

    Research and development (R&D) expenses in the first quarter of 2011 were $16.8 million compared with $20.5 million in the first quarter of 2010. 
    '/>"/>

    SOURCE InterMune, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. InterMune to Present at Canaccord Adams Conference
    2. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
    3. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
    4. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
    5. InterMune to Release Third Quarter 2008 Financial Results on November 6
    6. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
    7. InterMune to Present at Deutsche Bank Biotech Boston Confab
    8. InterMune to Present at J.P. Morgan Healthcare Conference
    9. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
    10. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
    11. InterMune Announces Issuance of U.S. Patent for ITMN-191
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/13/2014)... 2014 Deep Research Report on Global and ... study on the current state of the Nano Silver ... a basic overview of the industry, including definitions, applications ... domestic market analysis are provided with a focus on ... A comparison between the international and Chinese situation is ...
    (Date:7/11/2014)... WEST PALM BEACH, Fla. , July 11, 2014 ... wide variety of high-quality peptides that are used solely ... online. To honor two successful years in business, Maxim ... Performance LLC, has just launched a new and updated ... addition, the research blog section has been updated with ...
    (Date:7/11/2014)... DUBLIN , July 11, 2014 ... "International Transfection Technology Market - Global Industry Analysis, ... report to their offering. ... to introduce nucleic acids (either DNA or RNA) into ... therapy, mutation of cancer cells and protein metabolism by ...
    (Date:7/11/2014)... 2014 EPFL and the University of  ... of John P. Donoghue . The American neuroscientist ... . The new Wyss Center for ... Geneva , has named as its director ... P. Donoghue , founder of Brown University,s Institute for ...
    Breaking Biology Technology:2014 Nano Silver Industry in Global and China Regions Development Proposals Analysis Available at DeepResearchReports.com 22014 Nano Silver Industry in Global and China Regions Development Proposals Analysis Available at DeepResearchReports.com 3Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3
    ... Nov. 29 Martek Biosciences,Corporation (Nasdaq: MATK ... at,the upcoming ThinkEquity Partners ThinkGreen Conference in San ... 2007 at the St. Regis Hotel.,Steve Dubin, CEO, ... at 3:00,p.m. PST., A live audio webcast ...
    ... clinicians from Harvard, Stanford, University of, Washington, the Scripps ... Hospital partner with ... embryonic stem cells, by using pharmaceutical medicines to modulate stem ... and via the use of ,reprogrammed, adult stem ...
    ... 29 , - The Swiss Anecova Selected, ... the 39 visionary companies,selected as Technology Pioneers 2008. ... of them. The Technology Pioneers 2008 were nominated ... companies, academics and media. The final selection from ...
    Cached Biology Technology:Fate Therapeutics Created by Leading Stem Cell Scientists to Pursue New Approaches to Stem Cell Therapies 2Fate Therapeutics Created by Leading Stem Cell Scientists to Pursue New Approaches to Stem Cell Therapies 3Fate Therapeutics Created by Leading Stem Cell Scientists to Pursue New Approaches to Stem Cell Therapies 4Fate Therapeutics Created by Leading Stem Cell Scientists to Pursue New Approaches to Stem Cell Therapies 5The World Economic Forum Announces Technology Pioneers 2008 2The World Economic Forum Announces Technology Pioneers 2008 3
    (Date:7/10/2014)... 2, 2014  Unisys Corporation,s (NYSE: UIS ) ... N.V., today announced that it has been selected by the ... a new Basic Provision Biometrics solution for penitentiaries across ... the contract with a solution based on its open standards-based ... of the contract is up to seven years, with the ...
    (Date:7/10/2014)... 2014 NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication company focused ... Gino Pereira was interviewed on July 1 st ... Florida . Mr. Pereira discusses the company,s next generation ... and how the Wocket™ aims to replace a traditional wallet ... Cedric Harris tells Gino he has never heard of ...
    (Date:7/10/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/h7h8lq/gesture ... "Global Gesture Recognition & Touch-Less Sensing (2D, 3D, ... report to their offering ... & Touch-Less Sensing Market to Grow Exponentially. Touch-less ... but the companies were unable to leverage this ...
    Breaking Biology News(10 mins):Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 2Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 4Global Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, Capacitive) Market - Forecasts to 2020 2
    ... detect a crippling disease called QPX occurring in clam beds ... Although it does not affect humans and it is not ... a significant impact on a local economy by killing ... QPX - for quahog parasite unknown - is a single-celled ...
    ... genome of a microbiological master of adaptationArchaea, small ... they are able to live under extreme environmental ... pH-values, or high temperatures. Nature's masters of adaptation, ... draw conclusions about the first organisms on earth. ...
    ... that restoring a gene often silenced in lung cancer causes ... new strategy for treating the disease. , The research ... or silenced in a large majority of lung cancers, and ... pancreas. The work was led by scientists at The Ohio ...
    Cached Biology News:New genetic test can detect clam disease 2Life in deadly conditions 2Life in deadly conditions 3Restoring silenced suppressor gene kills lung-cancer cells 2
    ... The Rice Oligo Microarray, 22K ... of rice genes associated with biological ... abiotic stress response. Each microarray contains ... of the rice (japonica) genome focuses ...
    ... ELF 97 Cytological Labeling Kit provides a ... detection of cellular targets, including cell-surface receptors ... Labeling Kit contains the patented ELF 97 ... yellow-green precipitate at the site of enzymatic ...
    ... Ligands\n\nReceptor-related research has long been enabled by ... selected to keep pace with new discoveries. ... and services for receptor research and drug ... you do not find exactly what you ...
    ... Feature Extraction Software reads ... files to prepare microarray data ... , * one 2-year ... for NFP/Academic accounts , * ...
    Biology Products: